Mr. John Price reports

TELO GENOMICS CLOSES FIRST TRANCHE OF CONVERTIBLE DEBENTURES FINANCING

Telo Genomics Corp. has closed the first tranche of its previously announced non-brokered private placement offering of non-transferable secured convertible debentures (see news release dated Jan. 19, 2026) by issuing debentures for gross proceeds of $840,000.

The debentures bear interest at a rate of 15 per cent per annum, compounded quarterly, and will mature on Dec. 15, 2026. The principal amount of the debentures may, at the holder's election, at any time before the maturity date, be converted into common shares of the company at a conversion price of five cents per share. The company has no right to prepay the debentures prior to the maturity date.

In connection with the sale of the debentures, the company issued to the purchasers one transferable detachable warrant for every five cents of principal amount of the debentures subscribed for. The company issued an aggregate of 16.8 million warrants in connection with the first tranche. Each warrant will be exercisable to acquire one share at an exercise price of eight cents per share until Feb. 17, 2027.

The proceeds raised from the offering are expected to be used for lab trials and general working capital.

In connection with the first tranche, the company paid cash finders' fees of $58,800 and issued 1,176,000 finders' warrants. Each finders' warrant will be exercisable to acquire one share at an exercise price of eight cents per share until Feb. 17, 2028.

The offering is subject to certain conditions, including but not limited to receipt of all necessary approvals from the TSX Venture Exchange.

The debentures, warrants and finders' warrants issued in connection with the first tranche and any securities issuable upon conversion or exercise will be subject to a four-month-and-one-day hold period, expiring June 18, 2026, in accordance with applicable Canadian securities laws.

About Telo Genomics Corp.

Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases.

We seek Safe Harbor.